Furthermore, preclinical studies have demonstrated that pharmacological inhibition of NLRP3 attenuates disease severity in animal models of RA, highlighting the therapeutic potential of targeting NLRP3 inflammasome activation to treat RA. Here, NLRP3 is linked to rheumatoid arthritis.